Stockscreener 앱 받기
299.45
0.94%
-2.45
Bio Rad Laboratories Inc 주식(BIO)의 최신 뉴스
(BIO) Volatility Zones as Tactical Triggers - Stock Traders Daily
ETFs Investing in Bio-Rad Laboratories, Inc. Class A Stocks - TradingView
BIO5368763 Bond Coupon Profile — Rate & Payments - TradingView
BIO5368763 Bond Risk Profile - TradingView
BIO5368763 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Profile — Key Metrics - TradingView
BIO5368765 Bond Risk Profile - TradingView
BIO5368765 Bond Coupon Profile — Rate & Payments - TradingView
Bio-Rad unveils Vericheck ddPCR kits for QX700 QC - Select Science
Price to earnings forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
Price to earnings forward of Bio-Rad Laboratories, Inc. – BOATS:BIO - TradingView
Bio Rad Laboratories (BIO) Launches New ddPCR Kits Following A Fair Value Debate - Sahm
BIO Q1 2026 Earnings: EPS Falls Short of Expectations, Shares Edge LowerEPS Revision Trend - dars.gov.et
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 4.7% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad launches Vericheck ddPCR Kits compatible with QX700 platform for biopharma quality control and cell and gene therapy workflows - News-Medical
Bio-Rad Releases New Quality Control Kits for Cell and Gene Therapy - Clinical Lab Products
Bio-Rad Launches Vericheck ddPCR Kits Compatible with QX700 Platform for Biopharma Quality Control and Cell and Gene Therapy Workflows - Cambridge Network
Bio-Rad Laboratories outlines its diagnostics and life science strategy for long-term growth - Ad-hoc-news.de
BIOBio-Rad Laboratories Inc Volatility & Greeks - Finviz
Price to sales forward of Bio-Rad Laboratories, Inc. – NYSE:BIO - TradingView
BIO.B Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bio-Rad Laboratories outlines long-term growth drivers as life science demand evolves - Ad-hoc-news.de
Bio-Rad: Activist Involvement Highlights Value-Unlocking Potential (NYSE:BIO) - Seeking Alpha
BIO.B Technical Analysis & Stock Price Forecast - Intellectia AI
Bio-Plex Pro Human Cytokine Assays from Bio-Radmultiplex panels for immune research - ad-hoc-news.de
Bio Rad Laboratories (BIO) Following ddPCR Expansion Narrative Looks Fully Valued - Sahm
Bio-Rad Laboratories, Inc. (BIO) Stock Analysis: Evaluating Growth Amidst Stable Price Movements - DirectorsTalk Interviews
Oxidative Stress Assay Market Size to Reach USD 3.25 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (LSX:862449) - TradingView
Bio-Rad Laboratories, Inc. Class B Actuals & Estimates (FWB:BUW) - TradingView
Is It Too Late to Buy Bio-Rad Laboratories Inc (BIO) After 6.5% Rally? GF Value Says Undervalued - GuruFocus
Bio-Rad rises as life-science tools deal activity and activist interest appear to lift sentiment - Quiver Quantitative
Bio-Rad Laboratories, Inc. Class A Actuals & Estimates (NYSE:BIO) - TradingView
Bio-Rad Laboratories Jumps 5.6% Amid Sector-Wide Rally - AlphaStreet
BIO Forecast — Price Target — Prediction for 2027 - TradingView
Lyme Disease Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Abbott, Bio-Rad Labs, Covance Inc.F. Hoffmann-La Roche AG, T2 Biosystems - Barchart
Price-Driven Insight from (BIO) for Rule-Based Strategy - Stock Traders Daily
Bio-Rad vs. Charles River Labs: Which Medical Research Stock Is a Better Buy in 2026? - AOL.com
Bio Rad Laboratories Inc (BIOb) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
2x Valuation Gap: BIO vs. CRL — Who’s Wrong? - NAI500
IVD Quality Control Market Size, Share | Industry Report [2034] - Fortune Business Insights
Why Bio-Rad’s Bio-Plex Pro Human Cytokine Screening Panel still matters in the lab - ad-hoc-news.de
Bio Rad Laboratories Inc (BIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bio Rad Laboratories Inc (BIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
How Stronger Results and Institutional Selling At Bio-Rad Laboratories (BIO) Has Changed Its Investment Story - Sahm
Bio Rad Laboratories Inc (BIOb) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIOb) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIOb) Institutional Confidence - TradingKey
Bio Rad Laboratories Inc (BIOb) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bio Rad Laboratories Inc (BIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bio Rad Laboratories Inc (BIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bio Rad Laboratories Inc (BIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bio Rad Laboratories Inc (BIO) Institutional Confidence - TradingKey
Bio Rad Laboratories Inc (BIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bio Rad Laboratories Inc (BIOb) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bio Rad Laboratories Inc (BIOb) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Bio Rad Laboratories Inc (BIOb) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
0.16%
자본화:
|
볼륨(24시간):